S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Data Investigating KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, in Patients with Advanced Triple-Negative Breast Cancer Presented at 2014 San Antonio Breast Cancer Symposium (2014/12/10)|
|Merck Sales Fall on Stronger Dollar, Patent Expirations -- Update (2015/2/4)|
|Merck's Insomnia Medicine BELSOMRA® (suvorexant) C-IV, the First and Only Orexin Receptor Antagonist, Now Available in the United States (2015/2/3)|
|Merck to Team With NGM to Develop Diabetes and Obesity Treatments -- Update (2015/2/23)|
|Merck to Team With NGM to Develop Diabetes Treatment (2015/2/23)|
|Merck Profit Slips Despite Revenue Gains (2015/3/3)|
|Germany's Merck Cautious After Deal Spree -- Update (2015/3/3)|
|Merck Acquires OncoEthix, a Privately Held Oncology Company Developing Novel BET Inhibitors for Hematological and Solid Cancers (2014/12/18)|
|International Breast Cancer Study Group, Breast International Group and Merck Announce Opening of International PANACEA Study of Patients with HER2+ Breast Cancer (2014/12/10)|
|Data Investigating KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, in Patients with Classical Hodgkin Lymphoma Presented at ASH Annual Meeting (2014/12/6)|
Click above to view more mutual fund data and stats for merck - Merck Ltd.